<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02977065</url>
  </required_header>
  <id_info>
    <org_study_id>148HL16011</org_study_id>
    <nct_id>NCT02977065</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors</brief_title>
  <official_title>Multicenter, Parallel-group, Double-blind, Randomized, Active-controlled, Dose-ranging Study to Assess the Safety, Efficacy, and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors, in Subjects With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess
      the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor
      CKD-519 in combination with atorvastatin or rosuvastatin in subjects with dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the safety, efficacy, and tolerability of CKD-519,
      administered with HMG-CoA reductase inhibitors in subjects with dyslipidemia
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline (Visit 3) in LDL-C</measure>
    <time_frame>at Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in HDL-C</measure>
    <time_frame>at Weeks 2 and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in concentration of HDL particles (HDL-P)</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in size of HDL particles (HDL-P)</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in LDL-C</measure>
    <time_frame>at Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration from baseline in LDL-C</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration from baseline in HDL-C</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in total cholesterol, TG, and non-HDL-C</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration from baseline in total cholesterol, TG, and non-HDL-C</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), and apolipoprotein E (Apo E)</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration from baseline in Apo B, Apo A1, and Apo E</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in lipoprotein(a) (Lp-a)</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration from baseline in Lp-a</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration from baseline in high-sensitivity C-reactive protein at</measure>
    <time_frame>at Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg + CKD-519 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg + CKD-519 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg + CKD-519 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 10 mg + CKD-519 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>PO daily for 4weeks</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg + CKD-519 50 mg</intervention_name>
    <description>PO daily for 4weeks</description>
    <arm_group_label>Atorvastatin 20 mg + CKD-519 50 mg</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg + CKD-519 100 mg</intervention_name>
    <description>PO daily for 4weeks</description>
    <arm_group_label>Atorvastatin 20 mg + CKD-519 100 mg</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg + CKD-519 200 mg</intervention_name>
    <description>PO daily for 4weeks</description>
    <arm_group_label>Atorvastatin 20 mg + CKD-519 200 mg</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10 mg</intervention_name>
    <description>PO daily for 4weeks</description>
    <arm_group_label>Rosuvastatin 10 mg</arm_group_label>
    <other_name>Crestor 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10 mg + CKD-519 100 mg</intervention_name>
    <description>PO daily for 4weeks</description>
    <arm_group_label>Rosuvastatin 10 mg + CKD-519 100 mg</arm_group_label>
    <other_name>Crestor 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 80 years.

          2. Dyslipidemia with LDL-C

               -  At screening if untreated: 100 to 190 mg/dL

               -  At screening if treated with statins or other lipid-lowering drugs: 100 to 170
                  mg/dL

               -  At start of double-blind treatment: 100 to 190 mg/dL.

          3. HDL-C &lt;45 mg/dL (males) or &lt;50 mg/dL (females).

          4. Fasting TG &lt;400 mg/dL.

          5. Presence of the following conditions is permitted but not mandatory, at the discretion
             of the investigator:

               -  Treated and stable coronary heart disease without acute events in the past 3
                  months and stable, state-of-the-art medication.

               -  Treated and stable carotid artery disease or peripheral arterial disease on
                  stable, standard medication for the past 3 months

               -  Treated and stable Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c)
                  â‰¤9.5%.

          6. Willing and able to sign the informed consent form (ICF).

        Exclusion Criteria:

          1. Chronic heart failure as defined by New York Heart Association classes III and IV.

          2. Uncontrolled cardiac arrhythmias.

          3. Myocardial infarction, percutaneous coronary intervention, coronary artery bypass
             graft, or unstable angina in past 3 months before Visit 1.

          4. Stroke or transient ischemic attack within 3 months before Visit 1.

          5. Uncontrolled hypertension.

          6. Clinically significant laboratory abnormalities

               -  Aspartate aminotransferase or alanine aminotransferase &gt;2 times upper limit of
                  normal range

               -  Bilirubin &gt;1.5 times upper limit of normal range

               -  Creatine kinase &gt;2 times upper limit of normal range.

          7. Any active nephropathy or estimated glomerular filtration rate &lt;60 mL/min/1.73m2 or on
             kidney dialysis.

          8. Poorly controlled (thyroid-stimulating hormone [TSH] &gt;2 times upper limit of normal)
             hyperthyroidism.

          9. Homozygous familial hypercholesterolemia.

         10. Intolerance or hypersensitivity to atorvastatin or rosuvastatin.

         11. Prior treatment with any CETP inhibitor.

         12. Positive for human immunodeficiency virus (HIV) positive, hepatitis B or hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Mi Park, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chong Kun Dang Pharm.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji-Hye Lee, Manager</last_name>
    <email>jihye@ckdpharm.com</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>CETP Inhibitors</keyword>
  <keyword>Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

